Dear LabPulse reader;
This week, our top story involved transition at biopharmaceutical firm Kronos Bio, which announced a layoff as part of a corporate restructuring, as well as a change in its leadership.
Collaborative projects were among the other most-read stories this week, with biotech firm COUR Pharmaceuticals signing an agreement with Genentech for the development and commercialization of COUR's nanoparticle treatments for an undisclosed autoimmune disease. Meanwhile, Oxford Nanopore announced its collaboration with the UK Biobank on a project described as the world's first comprehensive, large-scale epigenetic dataset as part of an initiative to advance biomedical research. Oxford Nanopore is also contributing to a biosurveillance system as part of this initiative.
Google's announcement that it has released Health AI Developer Foundations (HAI-DEF) also garnered attention; HAI-DEF expands on Google's earlier research use only model to enable health AI development from early research to commercial ventures.
Rounding out the most-read articles this week, OraSure Technologies has been awarded federal funding through BARDA for the development of a rapid antigen test for Marburg virus disease, a severe infectious disease with no current approved vaccines or treatments.
Thanks for reading.
